CX 157

Drug Profile

CX 157

Alternative Names: CX157; KP 157; TriRima; Tyrima

Latest Information Update: 27 Jun 2013

Price : $50

At a glance

  • Originator Krenitsky Pharmaceuticals
  • Developer CeNeRx BioPharma
  • Class Antidepressants; Anxiolytics; Small molecules
  • Mechanism of Action Monoamine oxidase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Anxiety disorders; Major depressive disorder

Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 27 Jun 2013 Discontinued - Phase-II for Major depressive disorder (treatment-resistant) in USA (PO)
  • 27 Jun 2013 Discontinued - Phase-I for Anxiety disorders in USA (PO)
  • 27 Jun 2013 CX 157 is available for licensing globally as of 27 Jun 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top